Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

摘要: The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 a chemotherapy-refractory MCRC were included and clinical response was evaluated according to evaluation criteria solid tumours (RECIST). Tumours screened for mutations using first direct sequencing, then two sensitive methods based on SNaPshot PCR-ligase chain reaction (LCR) assays. Clinical gene the Fisher exact test. Times progression (TTP) calculated Kaplan–Meier method compared log-rank A detected 22 out and, six cases, missed by sequencing analysis but PCR-LCR Remarkably, no found 12 response. associated disease (P=0.0005) TTP significantly decreased mutated (3 vs 5.5 months, P=0.015). Our study confirms that is highly non-response highlights need use molecular methods, such as or assays, ensure an efficient detection.